



For Immediate Release

## **AMRI Relocates Bothell R&D Facility**

### *Laboratory Capacity Expanded to Support Demand for R&D Services*

Albany, NY (April 20, 2009)—AMRI (NASDAQ: AMRI) today announced that it has completed the relocation of its Bothell, Washington research unit into approximately 44,000 square feet of nearby newly refurbished laboratory and office space. Besides substantial improvements in operational efficiencies gained by consolidating all staff and services into one building, the new site provides capacity for growth, currently projected to be double the scale of the current operation over the next five years.

This investment demonstrates the company's continued commitment to providing high end technology focused on pharmaceutical lead discovery and optimization for customers as well as for AMRI's own internal drug discovery programs. The new Bothell facility is equipped to support future enhancements encompassing early biology and natural product drug discovery capabilities, furthering the company's ability to provide scientific services across a fully integrated drug discovery, development and manufacturing platform.

"We are pleased to announce the successful completion of this move that simultaneously positions us to continue to realize margin growth by executing on plans that provide significant cost savings, but that also sets the stage for future growth," said Chairman, CEO and President Thomas E. D'Ambra, Ph.D. "In this current business climate, we believe the pharmaceutical industry will continue to be challenged to simultaneously contain costs while continuing to populate new drug pipelines, resulting in an increased demand for outsourcing services."

#### **About AMRI**

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

#### **Forward-Looking Statements**

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, but are not limited to, statements by AMRI's Chairman, CEO and President and statements concerning the company's plans for its Bothell facilities, anticipated future capacity at such facilities and the performance of the company's

*(continued)*

global chemistry platform. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission on March 13, 2009 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.

-30-

**Contacts:**

Media – Andrea Schulz, AMRI Corporate Communications, 518-512-2226  
Investors – Peter Jerome, AMRI Director of Investor Relations, 518-512-2220

